💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Activists urge Biden to push for intellectual property waiver for COVID-19 vaccines

Published 11/22/2021, 01:19 AM
Updated 11/22/2021, 10:06 AM
© Reuters. FILE PHOTO:U.S. President Joe Biden speaks about the state of vaccinations during a coronavirus disease (COVID-19) response event in the East Room at the White House in Washington, U.S., March 18, 2021. REUTERS/Carlos Barria

By Andrea Shalal

WASHINGTON (Reuters) -Fifteen medical and human rights groups are urging U.S. President Joe Biden to get personally engaged in a long-running fight to enact an intellectual property waiver for COVID-19 vaccines at the World Trade Organization, calling his leadership "a moral necessity."

Amnesty International, Doctors without Borders, Human Rights Watch, Public Citizen and 11 other groups told Biden in a letter that an emergency waiver was urgently needed to combat the pandemic, noting that fewer than 7% of people in low-income countries had received a first COVID-19 shot and vaccines remained scarce.

More than 5.4 million people have died of COVID-19 around the world https://graphics.reuters.com/world-coronavirus-tracker-and-maps since the first cases were identified in China in December 2019.

Biden reversed the previous U.S. position to endorse a waiver in May https://www.reuters.com/business/healthcare-pharmaceuticals/biden-says-plans-back-wto-waiver-vaccines-2021-05-05, a move that caught some allies by surprise, but there has been little progress since then. The European Union, Britain and Switzerland remain opposed, arguing that issuing such waivers would undercut years of investment and research.

The White House last month called on all WTO members to support a temporary waiver https://www.reuters.com/world/us/white-house-wto-members-must-support-intellectual-property-waiver-covid-vaccines-2021-10-21 and WTO Director-General Ngozi Okonjo-Iweala is pushing for a deal at a WTO ministerial conference in Geneva from Nov. 30 to Dec. 3.

In their letter, a copy of which was viewed by Reuters, the rights groups said they were "very disappointed" that the Biden administration had not done more to secure an agreement on a waiver text since Biden's strong statement in May.

"U.S. passivity has empowered close U.S. allies - the European Union, on behalf of Germany, plus Switzerland and the United Kingdom - to block progress even as millions die or become seriously ill waiting for effective vaccines and treatments," the groups wrote.

They urged Biden to step up his personal engagement and lead the world in reaching a meaningful agreement on the long-standing issue. Doing so would help end the pandemic and restore U.S. standing around the world, they said.

Activists say they have gathered 3 million signatures on petitions urging Biden to step up U.S. efforts and will deliver them on Tuesday.

The White House had no immediate comment on the letter, which was dated Friday.

Ending the ministerial meeting without a waiver agreement would be entirely unacceptable," the groups said. They said drugmakers were using their intellectual property rights to segment global markets instead of maximizing the scale of generic production.

© Reuters. FILE PHOTO:U.S. President Joe Biden speaks about the state of vaccinations during a coronavirus disease (COVID-19) response event in the East Room at the White House in Washington, U.S., March 18, 2021. REUTERS/Carlos Barria

U.S officials oppose a separate effort to issue a "declaration on trade and health" led by David Walker, the New Zealand envoy to the WTO, according to a Geneva trade delegate and a second source briefed on the matter.

In their letter, the groups said the declaration, if passed without a meaningful intellectual property rights waiver, would "further undermine the WTO's relevance and legitimacy."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.